Dr. Miller's Work Will Concentrate on the Continued Development of Insmed's

                   Follow-On Biologics Product Portfolio



    RICHMOND, Va., July 28 /EMWNews/ -- Insmed Inc. (Nasdaq:

INSM), a developer of follow-on biologics and biopharmaceuticals, today

announced that Jim Miller, Ph.D. has joined Insmed's management team as

Vice President of Process Development. Dr. Miller will play an important

role in the development of Insmed Therapeutic Proteins' emerging portfolio

of follow-on biologics.



    Dr. Miller, 56, brings over 25 years of experience in biopharmaceutical

product research and preclinical development to his new position. Prior to

joining Insmed, he served as Executive Vice President of Product

Development at Saronyx, Inc., a private life sciences company that he also

co-founded. Dr. Miller earlier held senior development, operations and

research positions at both Reneneron Pharmaceuticals, Inc., and Amgen. His

strategic and management expertise, which center around the

biopharmaceutical development process, includes team management, research

design and implementation, strategic planning, product development, and

product marketing.



    Dr. Miller received his Ph.D. in Chemistry from the California

Institute of Technology and performed his Postdoctoral work at Yale

University School of Medicine. He has been published on numerous occasions

in well-respected scientific periodicals, including The Journal of

Neuroscience, The Archive of Biochemistry and Biophysics and The Journal of

Molecular Biology.



    Doug Farrar, Senior Vice President, Manufacturing Operations for Insmed

commented, "We are excited to have Jim join our experienced team. His

background is well suited to further accelerate progress on our follow-on

biologics portfolio as we reach a critical stage in the development process

of these product candidates."



    Dr. Miller commented, "I am pleased to be joining the Insmed team,

which has consistently demonstrated its advanced knowledge of biologics

development, manufacturing capability and its skilled scientific and

technical workforce. I am excited to be a part of the first U.S.-based

biotechnology company to develop a comprehensive portfolio of follow-on

biologics and look forward to working with the team to continue advancing

these product candidates as rapidly as possible through the development

process."

    About Insmed



    Insmed Inc. is a biopharmaceutical company with unique protein process

development and manufacturing experience and a proprietary protein platform

aimed at niche markets with unmet medical needs. For more information,

please visit http://www.insmed.com.



    Forward-Looking Statements



    This release contains forward-looking statements which are made

pursuant to provisions of Section 21E of the Securities Exchange Act of

1934. Investors are cautioned that such statements in this release,

including statements relating to planned clinical study design, regulatory

and business strategies, strategic alternatives, plans and objectives of

management and growth opportunities for existing or proposed products,

constitute forward-looking statements which involve risks and uncertainties

that could cause actual results to differ materially from those anticipated

by the forward-looking statements. The risks and uncertainties include,

without limitation, risks that strategic alternatives may never be

consummated, product candidates may fail in the clinic or may not be

successfully marketed or manufactured, we may lack financial resources to

complete development of product candidates, the FDA may interpret the

results of studies differently than us, competing products may be more

successful, demand for new pharmaceutical products may decrease, the

biopharmaceutical industry may experience negative market trends, our

entrance into the follow-on biologics market may be unsuccessful, our

common stock could be delisted from The NASDAQ Capital Market and other

risks and challenges detailed in the Company's filings with the U.S.

Securities and Exchange Commission, including the Company's Annual Report

on Form 10-K for the year ended December 31, 2007. Readers are cautioned

not to place undue reliance on any forward-looking statements which speak

only as of the date of this release. The Company undertakes no obligation

to publicly release the results of any revisions to these forward-looking

statements that may be made to reflect events or circumstances that occur

after the date of this release or to reflect the occurrence of

unanticipated events.






    Investor Relations Contact:

    Brian Ritchie - FD

    212-850-5683

    [email protected]



    Corporate Communications Contact:

    John Procter - Gibraltar Associates

    202-879-5808

    [email protected]